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Abstract
The impact of synthetic amyloid b (1–42) (Ab1–42) oligomers on biophysical properties of voltage-gated potassium channels
Kv 1.3 and lipid bilayer membranes (BLMs) was quantified for protocols using hexafluoroisopropanol (HFIP) or sodium
hydroxide (NaOH) as solvents prior to initiating the oligomer formation. Regardless of the solvent used Ab1–42 samples
contained oligomers that reacted with the conformation-specific antibodies A11 and OC and had similar size distributions as
determined by dynamic light scattering. Patch-clamp recordings of the potassium currents showed that synthetic Ab1–42
oligomers accelerate the activation and inactivation kinetics of Kv 1.3 current with no significant effect on current
amplitude. In contrast to oligomeric samples, freshly prepared, presumably monomeric, Ab1–42 solutions had no effect on
Kv 1.3 channel properties. Ab1–42 oligomers had no effect on the steady-state current (at 280 mV) recorded from Kv 1.3-
expressing cells but increased the conductance of artificial BLMs in a dose-dependent fashion. Formation of amyloid
channels, however, was not observed due to conditions of the experiments. To exclude the effects of HFIP (used to dissolve
lyophilized Ab1–42 peptide), and trifluoroacetic acid (TFA) (used during Ab1–42 synthesis), we determined concentrations of
these fluorinated compounds in the stock Ab1–42 solutions by
19F NMR. After extensive evaporation, the concentration of
HFIP in the 1006stock Ab1–42 solutions was ,1.7 mM. The concentration of residual TFA in the 706stock Ab1–42 solutions
was ,20 mM. Even at the stock concentrations neither HFIP nor TFA alone had any effect on potassium currents or BLMs.
The Ab1–42 oligomers prepared with HFIP as solvent, however, were more potent in the electrophysiological tests,
suggesting that fluorinated compounds, such as HFIP or structurally-related inhalational anesthetics, may affect Ab1–42
aggregation and potentially enhance ability of oligomers to modulate voltage-gated ion channels and biological membrane
properties.
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Introduction
Complex mechanisms that may contribute to Alzheimer’s
disease (AD) involve genetic and environmental factors [1,2] that
under some, often unknown, conditions converge to initiate the
onset of the neurodegeneration. Although the deposition of
aggregated amyloid b (Ab) peptide is the undisputed hallmark of
the disease, it has been shown that Ab also plays a physiological
role in the brain in its non-aggregated state [3,4,5] and that it may
function as an antibacterial peptide [6]. These diverse actions
suggest that peptide conformation and aggregate size of Ab
oligomers, often characterized by their immunological properties,
are crucial determinants of amyloid toxicity. Recent studies of
postmortem brain samples demonstrated a significantly higher level
of oligomers recognized by OC antibody [7] in AD patients
compared to healthy controls [8]. These polyclonal antibodies
recognize fibrillar oligomers that may represent fibril seeds or
small pieces of fibrils. Importantly, the level of OC-stained fibrillar
oligomers in the multiple brain regions correlates with the level of
cognitive decline and other neuropathological hallmarks of
Alzheimer’s disease [8]. It is still unclear, however, which type
of Ab oligomer initiates neurotoxic reactions in the brain and what
the molecular origins of these reactions are. In vitro studies suggest
that small soluble Ab oligomers, but neither monomeric nor
fibrillar forms of the peptide, are neurotoxic [9,10]. Multiple
mechanisms by which oligomers cause calcium dysregulation,
synaptic dysfunction, and ultimately neuronal cell death have been
proposed. These include amyloid interactions with cellular
membranes [11,12,13], the amyloid channel hypothesis [14,15],
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neurotransmitter receptors [21,22,23,24]. Results from artificial
membrane models parallel those of cell toxicology and physiolog-
ical studies [25,26], in that small soluble oligomers, but not
monomers or large aggregates such as fibrils, of amyloidogenic
peptides and proteins affect the conductance [27,28] and
structural integrity [12] of lipid membranes. On the other hand,
it has also been demonstrated that hexafluoroisopropanol (HFIP),
frequently used as a solvent for the peptide in the preparation of
amyloid oligomers, affects the conductance of bilayers and the ion
flux across cell membranes [29]. Because Ab has been associated
with characteristic pathological changes, these findings are in the
center of the debate whether the membrane effects of Ab
oligomers are at the core of AD etiology.
The important question of how the effects of endogenous, cell-
derived Ab peptide match those of synthetic peptide samples
remains unresolved in large part because of the variety of methods
for Ab oligomer preparation used in different laboratories. In this
work, we compare quantitatively the properties of Ab oligomers
formed by two common protocols, one using HFIP and the other
NaOH as solvents to initiate the preparation of homogeneous
oligomer samples. In a widely used procedure, HFIP is added to
dissolve lyophilized Ab peptide. Subsequently water is added to
the monomeric peptide solution to initiate aggregation. To remove
the fluorinated solvent the resulting solution is stirred in ambient
air to allow the highly volatile HFIP to evaporate. The biophysical,
toxicological and immunological characteristics of such prepara-
tions have been extensively studied [27,30,31,32], and it was
shown that they increase the conductance of lipid bilayers and
influence both resident conductance mechanisms in cells and
specific conductance mechanisms introduced into planar lipid
bilayers [12,28]. Yet it has also been demonstrated that similar
effects are elicited by HFIP alone [29]. Another potential
contaminant of the synthetic peptides is trifluoroacetic acid
(TFA), which is commonly used in peptide synthesis and as
solvent of lyophilized peptide. Although extensively removed
during purification and lyophilization, it is toxic to cells at high
concentration. Moreover, TFA activates some types of potassium
channels [33]. It is therefore critical to determine which effects are
due to Ab oligomers and which to HFIP or TFA.
Here we use
19F NMR to quantify residual HFIP and TFA in
synthetic Ab oligomer samples, and test whether these compounds
contribute to electrophysiological effects. We compare the effects
of Ab oligomers prepared with HFIP on voltage-gated Kv 1.3
potassium channels and on freestanding bilayer lipid membranes
(BLMs) with those of HFIP-free oligomers prepared by initially
dissolving the lyophilized peptide in NaOH. The oligomer
preparations resulting from these protocols are further compared
in their structural properties with dynamic light scattering (DLS)
and characterized by their immunoreactivity.
Results
Size and conformation of Ab1–42 aggregates prepared
with HFIP or NaOH
To compare the sizes and size distributions of Ab1–42 aggregates
prepared by different protocols at similar time points after
initiating oligomer formation, we used dynamic light scattering
(DLS). Figure 1 shows distributions of Ab1–42 aggregate sizes,
evaluated under the assumption of spherical particles, obtained
through inversion of the DLS data by a RILT algorithm and
application of the Stokes-Einstein relation. Figure 1A–F show
these distributions 2 and 4 days after initial solubilization with
(Fig. 1A–D; HFIP protocols I and II) and without (Fig. 1E–F; NaOH
protocol) HFIP. Both preparations are fairly stable in time but
distinctly different, even under the uncertainty of the RILT
inversion algorithm. The resulting distributions show main
centroids that are shifted to slightly higher dh for those prepared
with HFIP than those prepared with NaOH, dh<40 nm, 41 nm,
and 21 nm for HFIP protocols I and II and the NaOH protocol,
respectively, at t=48 h. In addition, the Ab1–42 preparation from
HFIP protocol II shows a greater proportion of larger aggregates in
solution, as shown qualitatively by the secondary peak in Figs. 1C
and D. The ratio of larger to smaller Ab1–42 aggregates is ,1/440
for HFIP protocol II and ,1/4600 for the NaOH protocol. On the
other hand, the main centroids of the size distributions do not shift
significantly (from dh<40 to 38 nm and from <41 to 43 nm for
HFIP protocols I and II, and from dh<21 to 23 nm for the NaOH
protocol) between days 2 and 4, indicating stable aggregates persist
throughout the typical time range of bilayer conductance and
patch clamp experiments.
Not only the size but also the conformation of amyloid
aggregates may affect their cytotoxicity and their ability to interact
with cell membranes. Depending on the method and conditions of
the Ab sample preparation in vitro, different conformational states
of aggregates may form, including prefibrillar oligomers, fibrillar
oligomers, protofibrils, annular protofibrils, or mature fibrils
[31,34]. We used the conformation-specific antibodies, OC [7]
and A11 [30], which recognize generic epitopes independent of
amino acid sequence, to characterize Ab samples. OC recognizes
fibrillar oligomers and fibrils with a broad distribution of oligomer
sizes from approximately 8 kDa to 200 kDa (,3n mt o,8 nm).
On the other hand, A11 recognizes prefibrillar oligomers of
intermediate sizes. Figure 1G shows that, independently of the
protocol used, the resulting Ab1–42 solutions contained substantial
Figure 1. Size and conformation of Ab1–42 aggregates. (A–F) Size
distributions of Ab1–42 aggregates at different time points, as
determined with DLS. (A–D) Ab1–42 samples prepared with HFIP: (A, B:
protocol I;C ,D :protocol II) (E, F) Ab1–42 samples prepared with NaOH
and incubated at pH=7. A, C, F show samples incubated for 48 h and B,
D, F show samples incubated for 4 d at room temperature. Data taken
at T=2560.1uC. (G) Dot blots probed with A11 and OC antibodies show
that both A11-positive and OC-positive material is contained in the Ab1–
42 samples after 4 days of incubation. Representative blots are shown
(n$2 for each condition).
doi:10.1371/journal.pone.0035090.g001
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previously implicated in AD pathology. Thus, qualitatively, all
Ab1–42 samples were similar, although they might contain different
proportions of particular types of aggregates.
Residual fluorinated solvents in Ab1–42 samples
Because residual HFIP and/or TFA in Ab1–42 samples may
critically influence aggregate properties and contribute to effects
observed in the electrophysiological experiments, we used
19F
NMR as a sensitive method to quantify small concentrations of
fluorinated substances in samples with or without Ab1–42 (Fig. 2).
The fluorine peak at about 275.7 ppm is characteristic of
dissolved HFIP in the absence of peptide and originates from
the two CF3 moieties (Fig. 2A). The peak at about 275.5 ppm is
due to dissolved TFA in the absence of peptide (Fig. 2B). Ab1–42
samples prepared with HFIP protocol I, for which we assumed in
earlier work that HFIP was quantitatively removed [12,27,28],
contain residual HFIP for which the signal is slightly shifted upfield
to <275.744 ppm (Fig. 2C, left). Even if the HFIP is evaporated
from Ab1–42 samples in open Eppendorf tubes (HFIP protocol II), a
residual fluorine peak at –75.75 ppm was detected in ,30% of the
samples, albeit with a significantly reduced intensity (Fig. 2C,
middle). In contrast, Ab-free samples that initially contained HFIP,
which was removed by extensive evaporation in open Eppendorf
tubes, show no signal above noise at the spectral position
characteristic of HFIP (data not shown). As expected, this signal
was also not observed in samples prepared by using NaOH as
solvent (Fig. 2C, right), whereas TFA peaks (at –75.5 ppm) were
detected in all Ab1–42 oligomer samples regardless of the
preparation protocol used.
Calibration curves were determined for the HFIP and TFA
concentrations in aqueous solutions by using samples with known
concentrations of the fluorinated compounds and determining the
signal strengths at standardized instrument settings (Fig. 2D, F). In
Ab1–42 stock solutions prepared by HFIP protocols I ([Ab1–
42]=70mM) and II ([Ab1–42]=100 mM), the average contents of
HFIP estimated from the observed peak areas in the
19F NMR
signal were 10.4161.72 mM and 1.761 mM, respectively
(Fig. 2E). After dilution of these stock solutions to the Ab1–42
concentration used for electrophysiological experiments ([Ab]=1
to 6 mM), the HFIP concentration would be ,1 mM for samples
prepared following protocol I, and not more than 0.1 mM, for
samples prepared following protocol II. The concentration of
residual TFA in 70 mMA b1–42 stock solutions was 20 mM
(Fig. 2G).
HFIP and TFA affect neither Kv1.3 channels nor BLM
conductance
A recent study showed that HFIP alone modulates the
properties of biological membranes [29]. In the light of the
hypothesis that Ab oligomers affect neuronal membranes and may
interfere with cognitive functions by a membrane-dependent
mechanism, this raises the question if effects reported earlier as Ab
oligomer-specific are augmented by or entirely attributable to the
presence of residual HFIP. Furthermore, TFA can activate ATP-
sensitive potassium channels at concentrations as low as 0.05 mM
[33].
Therefore, we first quantify the effects of HFIP and TFA on
Kv 1.3 currents and BLM conductance. In patch clamp experi-
ments, high concentrations of HFIP (3–30 mM) reduce the Kv 1.3
peak current amplitude (Fig. 3A, C). In addition, HFIP accelerates
kinetics of the K
+ current at lower concentrations (<1–3 mM),
although the effect on inactivation time constants is not significant
(Fig.3D,E).TFAhadnoeffectonKv 1.3currentsatconcentrations
up to 1 mM and only at higher concentrations slowed the
inactivation rate, consistent with the low-pH effect on C-type
inactivation [35] (Fig. 3B). Figure 3F, G shows that HFIP itself also
increases the BLM conductance in a dose-dependent manner,
starting at concentrations .1 mM. A characteristic threshold for
HFIP effects on K
+ currents through Kv1.3 as well as on BLM
conductanceis<1 mM.Whilethisthresholdiscomparablewiththe
HFIP level in Ab1–42 samples prepared by HFIP protocol I,i ti s
significantly higher than the HFIP level in Ab1–42 samples prepared
by HFIP protocol II. Thus neither HFIP nor TFA are present in Ab
oligomer samples prepared by protocol II or NaOH protocol at the
concentrations that could contribute to the observed effects on K
+
currents or BLM conductances.
Ab1–42 oligomers prepared by HFIP protocol I: Effects on
Kv 1.3 currents and BLM conductances
Ab1–42 solutions prepared by HFIP protocol I contain heteroge-
neous populations of aggregates in which different oligomeric
species are present at distinct time points of the incubation period.
However, DLS shows that Ab1–42 oligomers do not significantly
change between days 2 and 4 after initiation of the preparation, a
time range in which the electrophysiological measurements were
conducted.
The effect of Ab1–42 aggregates prepared according to HFIP
protocol I on the currents and kinetics of Kv 1.3 is shown in Fig. 4.
The K
+ current is strongly affected by acute perfusion of the cells.
The peak current amplitude tends to increase at low voltages and
to decrease at the higher voltages (Fig. 4 A, B), and both activation
and inactivation kinetics are accelerated in a voltage-dependent
manner (Fig. 4 C–F). The concentrations of HFIP in the
extracellular solutions were less than 1 mM, a concentration too
small to account for the observed effects by the action of HFIP
alone, as a comparison of Figs. 3 and 4 shows.
Although Ab1–42 had no effect on ionic currents at the holding
membranepotential(280 mV)recordedincells,theconductanceof
the artificial lipid bilayer membranes was increased by Ab1–42
aggregates in a dose-dependent manner, consistent with our earlier
finding [28]. Figure4G showsrepresentativecurrent-voltage curves
measured in dioleoylphosphatidylcholine/dioleoylphosphatidy-
lethanolamine (DOPC/DOPE) BLMs bathed on both sides with
10 mM KCl. Panel H shows the average current at +150 mV
induced in such bilayers as a function of Ab1–42 concentration. In
these experiments, the residual HFIP concentration (Fig. 4H) is
#0.3 mM,asestimatedby
19FNMR,andacomparisonofFigs.3F,
G and 4G, H reveals that the effects of the peptide at 2 mMA b1–42
are still significantly greater than those of 1 mM HFIP alone.
Ab1–42 oligomers prepared by HFIP protocol II: Effects on
Kv 1.3 currents and BLM conductances
Ab1–42 samples prepared by HFIP protocol II contain a
population of larger aggregates in addition to smaller aggregates
contained in both HFIP protocol I-, and II- samples as indicated by
the secondary peak in Figs. 1C and D.
The HFIP protocol II samples tended to modulate Kv 1.3
potassium current properties (Fig. 5A–F) and increased bilayer
conductance (Fig. 5G, H) in a similar fashion to Ab1–42 samples
prepared by HFIP protocol I, although the effects were only
observed at higher concentrations of Ab1–42. At the lower
concentrations (1 and 3 mM) Ab1–42 produced no effect on
potassium currents (data not shown). Current amplitudes and the
activation kinetics were not significantly affected (Fig. 5A, B, and
C, D) and the effects on inactivation kinetics were less prominent
(Fig. 5E, F), reaching significance level when analyzed by paired t-
Synthetic Ab Effects on Kv1.3 Channels and BLMs
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35090Test, but not by repeated measures ANOVA. These effects can
not be attributed to residual free HFIP in the solution, as the
fluorine peaks revealed by
19F NMR in Ab1–42 samples prepared
by HFIP protocol II are extremely small.
Ab1–42 oligomers prepared by the NaOH protocol: Effects
on Kv 1.3 currents and BLM conductances
Although Ab1–42 samples prepared by the NaOH protocol contain
a larger aggregates, in addition to smaller aggregates population,
the proportion of larger aggregates in Ab1–42 samples prepared by
the NaOH protocol is much lower than in the Ab1–42 samples
prepared by HFIP protocol II (Figs. 1C–F).
HFIP-free Ab1–42 oligomer samples prepared by the NaOH
protocol modulated the Kv 1.3 current similarly to Ab oligomers
prepared by HFIP protocol I (Fig. 6A–E). However, higher peptide
concentrations (up to 10 mM) were required to produce similar
effects on current kinetics and the peak K
+ current amplitudes
remained unchanged (Fig. 6A, right). At the lower concentrations
Ab1–42 produced no significant effect on potassium currents (data
not shown). Freshly prepared Ab1–42 solutions (aggregated for less
than 1 hr) had no effect on K
+ current properties (Fig. 6A, left),
whereas oligomers aggregated for 48 hrs facilitated current
activation (Fig. 6B, C) and accelerated inactivation kinetics in a
voltage-dependent manner (Fig. 6D, E). Since these preparations
are entirely free of HFIP, these results show that the effects on
Kv 1.3 current are specific for Ab1–42 oligomers. For BLM
recordings, we used Ab1–42 at concentrations up to 2 mM. The
increase of bilayer conductance was observed at concentrations as
low as 0.25 mMA b1–42 (Fig. 6F, G). Overall, these results
demonstrate that Ab1–42 oligomers modulate Kv 1.3 potassium
channel properties and lipid bilayer conductances. The potency of
Figure 2. Quantification of HFIP and TFA in aqueous solutions by
19F NMR. (A) Ab-free aqueous solution spiked with 0.1 mM HFIP. (B) Ab-
free aqueous solution spiked with 0.13 mM TFA. (C)
19F NMR spectra of Ab1–42 oligomer samples prepared using HFIP protocol I, HFIP protocol II, and
the NaOH protocol. The signal amplification differs greatly between spectra as indicated by the different noise levels. The concentrations of Ab1–42
and HFIP prior to evaporation were 70 mM and 1.2 M. Black and red arrows indicate peaks originating from residual TFA and HFIP, respectively. (D, F)
Calibration standards generated by integrating the area under the
19F peaks obtained from samples with known HFIP (D) or TFA (F) concentrations.
The lines correspond to the best fits through the origin (R
2=0.999 for both fits). (E) HFIP concentrations 6 S.E.M. in stock Ab1–42 samples prepared
according to HFIP protocols I (n=6) and II (n=7). (G) TFA concentration 6 S.E.M. in stock Ab1–42 samples prepared according to NaOH protocol (n=2).
doi:10.1371/journal.pone.0035090.g002
Synthetic Ab Effects on Kv1.3 Channels and BLMs
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35090these effects depends on the oligomer preparation method,
suggesting that fluorinated solvents, such as HFIP, may signifi-
cantly alter properties of the resulting Ab1–42 oligomer samples,
augmenting their effects on membranes and ion channels.
Discussion
We demonstrate in this study that Ab1–42 oligomers, likely
causal agents of AD, modulate the kinetics properties of the
voltage-gated Kv 1.3 channels heterologously expressed in mam-
malian cells, and confirm that such aggregates also affect
properties of artificial lipid bilayer membranes. In distinction
from earlier work [28], we characterize the composition of the
peptide aggregates here more rigorously with respect to residual
fluorinated solvents and observe these effects regardless of whether
the Ab samples were prepared by dissolving the amyloid peptide in
HFIP or in NaOH to initiate aggregate formation (Figures 4, 5, 6).
This implies that residual fluorinated compounds, HFIP or TFA,
in synthetic Ab1–42 samples cannot account for the observed effects
and shows that small soluble amyloid oligomers modulate voltage-
gated potassium channels and interact with cell membranes,
resulting in dysregulation of ionic homeostasis, which may
ultimately lead to cell death [36].
It was previously shown that Ab oligomers modulate voltage-
gated calcium [5,17,20,37] and potassium channels
[16,18,19,38,39] directly or indirectly, by changing the properties
of the membrane. It is unlikely, however, that the effects on Kv 1.3
current kinetics reported here are mediated by membrane-related
effects because we did not observe any consistent changes in the
resting current, cell capacitance or resistance in the presence of
oligomers. The finding that Kv 1.3 channels are affected by
amyloid oligomers opens the possibility that Kv 1.3, and
potentially other Shaker family-related K
+ channels, might be
involved in the cascade of events leading to the dysfunction of
synaptic transmission in the brain in AD. Indeed in the rodent
brain, Kv 1.3 channels are expressed in the structures implicated
in AD, such as the olfactory bulbs, olfactory cortex, hippocampus,
and cerebellar cortex [40,41,42,43,44,45,46], where they have
differential subcellular localization and regulate the repolarization
of action potentials and neuronal firing patterns [47]. Speeding up
of the activation and C-type inactivation kinetics of Kv 1.3 by Ab
oligomers may cause significant changes in neuronal firing rates
Figure 3. HFIP and TFA effects on Kv1.3 channel currents and BLM conductance. (A) Representative current traces before (black) and after
(red and blue) application of HFIP (n=5 cells). (B) Representative current traces before (black) and after (red) application of TFA (n=3 cells). The
current-voltage relations before and after application of HFIP (A) or TFA (B) are shown in the inserts. (C) Dose-response curve for the HFIP effect on
peak K
+ currents, evoked by depolarizing steps to +40 mV. IC50=5.263.4 mM from fitting the data (mean 6 S.E.M., n=5 cells for each concentration)
to a Boltzmann function. (D) Activation of Kv 1.3 current is accelerated by HFIP (Data shown as mean 6 S.E.M., n=3 cells). The effect of HFIP on the
activation time constant was significant (F=50.6;
#P=0.01, Two-way RM-ANOVA) with significant interaction between FactorA (treatment) and
FactorB (voltage) (F=155), and by Pairwise Comparisons at 220 mV (*P=7.9969610
26, Tukey test). (E) The inactivation kinetics of Kv 1.3 current are
not significantly affected by HFIP (mean 6 S.E.M., n=3 cells,
#P=0.36369, Two-way RM-ANOVA). (F) Representative I/V curves recorded on DOPC/
DOPE BLMs in the presence of HFIP. (G) Dose-dependence of HFIP-induced currents through BLMs at +150 mV (mean 6 S.E.M. for n=7).
doi:10.1371/journal.pone.0035090.g003
Synthetic Ab Effects on Kv1.3 Channels and BLMs
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35090and thus disrupt normal synaptic transmission. While the present
work provides no direct evidence for binding of Ab oligomers to
Kv 1.3, it can not be excluded that synaptic accumulation of
soluble Ab oligomers, facilitated by increased synaptic activity
[48], might be associated with modulation of presynaptic Kv
channels by Ab oligomers. In addition, modulation of Kv 1.3
properties by Ab oligomers may also affect their non-traditional
scaffolding functions [49], such as interaction with neurotrophic
tyrosine receptor kinase B (trkB) [46,50,51] and b-integrins
[52,53]. Thus, it can not be excluded that Ab effects on Kv 1.3
are contributing to impaired BDNF/trkB signaling in AD brain
[53,54,55]. Furthermore, integrin-dependent activation of microg-
lia by Ab [56,57] induces up-regulation of Kv 1.3 channels
[58,59] which, in turn, is crucial for maintenance of the activation
Figure 4. Effect of Ab1–42 oligomers (HFIP protocol I) on Kv 1.3 currents and on BLM conductance. (A) Representative K
+ currents evoked
by depolarizing voltage steps from holding potential of 280 mV before (black) and after (red) application of Ab1–42 oligomers. (B) Peak K
+ currents
normalized to mean control values at different voltages before (black) and after application of Ab1–42 oligomers (red). Data are shown as mean 6
S.E.M. (n=6 cells). HFIP had no significant (n/s) effect on the peak current (F=0.17; P=0.69, Two-way RM-ANOVA). (C–F) Activation and inactivation
kinetics of K
+ currents before (black) and after application of Ab1–42 oligomers (red) shown in absolute (C, E) and normalized (D, F) values of time
constants at different voltages (mean 6 S.E.M., n=6 cells). The effect of Ab on the activation time constant was significant in Tests of Within-Subjects
Effects (F=46.8;
#P=4.7610
24, Two-way RM-ANOVA), with significant interaction between FactorA (treatment) and FactorB (voltage) (F=25.9), and
by Pairwise Comparisons at 220 mV (*P=2.08610
24, Tukey test). The effect of Ab on the inactivation time constant was also significant in Tests of
Within-Subjects Effects (F=8.1;
#P=0.04, Two-way RM-ANOVA), and by Pairwise Comparisons at 220 mV, 210 and 0 mV (*P,0.05; Tukey test). (G)
Representative I/V curves recorded on DOPC/DOPE BLMs before (black) and after (red) application of Ab1–42 oligomers. (H) Dose-dependence of Ab1–
42-induced currents at +150 mV across BLMs (mean 6 S.E.M., n=11 experiments, out of a total of 16, in which the effect was observed). HFIP
concentrations estimated from
19F NMR spectra of the Ab1–42 stock solutions are shown on the top axis.
doi:10.1371/journal.pone.0035090.g004
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modulation by Ab and functional changes in microglia in the
course of AD. Finally, Kv 1.3 channels have been linked to
proliferation of neuronal progenitor cells [60]. Growing evidence
suggests that neurogenesis is altered in AD patients
[61,62,63,64,65,66] and AD animal models [67,68,69,70], and it
is possible that modulation of Kv 1.3 channels by Ab oligomers
may contribute to these changes.
Figure 5. Effects of Ab1–42 oligomers (HFIP protocol II) on Kv 1.3 currents and on BLM conductance. (A) Representative K
+ currents evoked
by depolarizing voltage steps from the holding potential of 280 mV before (black) and after (red) application of Ab1–42 oligomers. (B) Peak K
+
currents normalized to mean control values at different voltages after application of Ab1–42 oligomers. The differences in peak current amplitude
before and after application of Ab are not significant (F=3.9; P=0.08 two-way RM-ANOVA). (C–F) Activation and inactivation kinetics of K
+ currents
before (black) and after application of Ab1–42 oligomers (red) shown in absolute (C, E) and normalized (D, F) values of time constants at different
voltages (mean 6 S.E.M., n=4 cells). The effect of Ab on the activation time constant was not significant in Tests of Within-Subjects Effects (F=4.4;
#P=0.07, Two-way RM-ANOVA). ANOVA analysis also revealed no significant effect of Ab on the inactivation time constant (F=8.7;
#P=0.05, Two-
way RM-ANOVA), however two-way paired t-Test, (
++P,0.05) showed significant differences between mean time constant measured before and after
treatment with Ab, revealing the trend. (G) Representative I/V curves recorded on DOPC/DOPE BLMs before (black) and after (red) application of Ab1–
42 oligomers. (H) Dose-dependence of Ab-induced currents at +150 mV across BLMs (mean 6 S.E.M., n=7 experiments, out of a total of 9, in which
the effect was observed).
doi:10.1371/journal.pone.0035090.g005
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e35090An equally important result is the observation that HFIP, a
frequently used solvent in peptide chemistry, can be retained in
peptide aggregate samples even after extensive evaporation. As
Fig.2(D,E)shows,
19FNMRprovidesafacileandsensitivemeansto
quantify HFIP concentration in aqueous solution with or without
Ab1–42. We confirm that HFIP per se alters the kinetics properties of
Kv 1.3 and, as we report here, increases the conductance of BLMs
[29] as well. However, these effects only occur at HFIP
concentrations that are much higher than those of the residual
solvent detected in HFIP-prepared Ab1–42 oligomer samples. The
Figure 6. Effect of HFIP-free Ab1–42 oligomers (NaOH protocol) on Kv 1.3 current and on BLM conductance. (A) Representative K
+
currents evoked by depolarizing voltage steps from the holding potential of 280 mV before (black) and after (red) Ab1–42 application. Note, that Ab1–
42 samples aggregated for less than 1 hr and presumably contained monomeric peptide, had no effect on K
+ current (A, left), whereas samples
aggregated for 48 hrs produced characteristic effect on K
+ current kinetics (A, right). (B–E) Activation and inactivation kinetics of K
+ currents before
(black) and after application of Ab1–42 oligomers (red) shown in absolute (B, D) and normalized (C, E) values of time constants at different voltages
(mean 6 S.E.M., n=4 cells). The effect of Ab on the activation time constant was significant in Tests of Within-Subjects Effects (F=34.5;
#P=0.009,
Two-way RM-ANOVA) with significant interaction between FactorA (treatment) and FactorB (voltage) (F=38.03), and by Pairwise Comparisons at
220 mV (*P=0.006, Tukey test). The effect of Ab on the inactivation time constant was also significant in Tests of Within-Subjects Effects (F=19.1;
#P=0.022, Two-way RM-ANOVA) with significant interaction between FactorA (treatment) and FactorB (voltage) (F=7.1), and by Pairwise
Comparisons at 220 mV (*P=0.016, Tukey test). (F) Representative I/V curves recorded on DOPC/DOPE BLMs before (black) and after (red)
application of Ab1–42 oligomers. (G) Dose-dependence of Ab-induced currents at +150 mV across BLMs (mean 6 S.E.M., n=5 experiments, out of a
total of 12, in which the effect was observed).
doi:10.1371/journal.pone.0035090.g006
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35090effects of HFIP alone on Kv 1.3 kinetics and BLM conductance
(Fig. 3) can be compared with those of HFIP-containing Ab1–42
aggregates prepared with HFIP protocol I (Fig. 4) where the HFIP
concentration in Ab1–42 stock solution with an amyloid concentra-
tion of 70 mM was 10.461.7 mM. Thus when diluted to 1 mM
peptide, the HFIP concentration in the electrophysiology measure-
ments is expected to be <140 mM. At this HFIP concentration, the
current acrossa BLM under the conditions specified inFig.3 would
be ,10 pA. In the presence of Ab1–42 oligomers, the current is
.100 pA(seeupperabscissainFig.4H).Thus,residualHFIPalone
cannot account for the increased lipid bilayer conductance induced
by HFIP-prepared oligomers, even when the evaporation is
performed with the less efficient separation procedure, HFIP
protocol I. The same conclusion is reached by analyzing the effects
of HFIP alone and of HFIP-prepared oligomers on the kinetics of
Kv 1.3. Figure 3A shows the effects of 3 mM HFIP on the kinetics
and amplitude of Kv 1.3 currents. Comparison of these results with
the effects of 1 mMA b1–42 oligomers prepared according to HFIP
protocol I,Fig.4,showsthattheestimatedHFIPconcentrationinthe
samples (<140 mM)isfar toosmall to accountfor the largeeffect on
Kv 1.3 peak currents and kinetics. The difference between the
electrophysiological effects of HFIP-prepared oligomers from those
of equivalent amounts of freely dissolved HFIP is even larger for
aggregates prepared following HFIP protocol II. Here, the HFIP
concentration in the peptide stock solution (<100 mMA b1–42)i s
1.761 mM. Thus, the estimated HFIP concentration in electro-
physiology measurements at 1 mMA b1–42 is 0.017 mM. The
intrinsic HFIP effects at this level are too small to observe above
noise in BLM current measurements (note the nonlinear dose-
response curve in Fig. 3G) or to distinguish from control in Kv 1.3
currentmeasurements.ThustheeffectsobservedwithAboligomers
prepared by HFIP protocol II cannot be due to residual HFIP.
In the light of the hypothesis that endogenous Ab oligomers
affect neuronal cells by altering membrane properties or
modulating voltage-gated ion channels, the critical question is
whether or not HFIP-free amyloid aggregates, such as those
prepared following the NaOH protocol, elicit measurable effects on
membranes and channels. Figure 6 shows that Ab1–42 oligomers
prepared by NaOH protocol alter Kv 1.3 currents kinetics and
increase the BLM conductance substantially at amyloid peptide
concentrations of <10 mM. We thus conclude that amyloid
oligomers themselves affect properties of Kv 1.3 potassium current
and lipid bilayer membranes. On the other hand, our study
determines clear quantitative differences between the effects of
Ab1–42 oligomers prepared by the different protocols, in particular
between HFIP protocol I versus HFIP protocol II and NaOH protocol.
While protocol II aggregates show similar characteristics to NaOH
protocol aggregates, HFIP protocol I produces aggregates that are
significantly more effective on membranes (compare Fig. 4 with
Figs. 5 and 6). Because the concentration of HFIP in Ab samples
prepared by HFIP protocol I is too low to account for the observed
effects by itself, these data suggest that HFIP interacts with Ab
peptide, potentially affecting intrinsic properties of the amyloid
aggregates or the aggregation process.
In DLS, the scattered light intensity depends on the hydrody-
namic radius of the particles as I(dh),dh
6. Therefore, in
polydisperse samples the scattering from larger aggregates
obliterates that from smaller ones. The reported size distributions
(Fig. 1A–F) with main peaks around dh<40 nm, <41 nm, and
<21 nm for the HFIP protocols I and II and the NaOH protocol
particles, respectively, do not rule out the presence of smaller Ab1–
42 aggregates in solution that would go undetected by DLS. It is, in
fact, unlikely that the 20 nm peaks correspond to the smallest
aggregate sizes present in the solutions. The number of peptide
molecules contained in a spherical aggregate of the hydrodynamic
diameter dh, which includes a hydrodynamically stagnant layer of
solvent, can be roughly estimated as follows. With Vh, Vp and dp
denoting, respectively, the hydrodynamic volume and the volume
and diameter of the peptide core, the stagnant solvent layer
occupies a volume, Vh2Vp=(p/6)(dh
32dp
3). Accounting for the
packing efficiency, w, of peptides in an aggregate, the volume
occupied by peptide in an aggregate is wVp. Assuming that a
stagnant layer around the dissolved aggregate is <10 A ˚ thick [71],
w<0.74 [72], and the average (hydrated) amino acid volume to be
vaa< 200 A ˚ 3, an upper limit for the number of Ab1–42 peptides in
an aggregate is given by np<wVp/(vaa642)<270 and np<2400 for
samples prepared with HFIP protocol II and the NaOH protocol,
respectively. From these estimates, it appears that the aggregates
observed in DLS are not the oligomer species that are believed to
be the origin of the biophysical effects on membranes and
toxicological effects on neuronal cells [25,26,27]. Rather, it is likely
that these samples contain smaller oligomers, invisible to DLS,
which might be identified by their immunological signatures. The
smaller proportion of the larger aggregates revealed by DLS in the
samples prepared by HFIP protocol I compared to other protocols is
associated with the strongest effect of Ab on Kv 1.3 channels as
well as on the BLM, suggesting that smaller aggregates are
affecting properties of the Kv 1.3 channels and lipid bilayers in our
experiments. Finally, the analysis of DLS data suggests that the
effective concentrations of the oligomers of smaller sizes in Ab
samples would be much lower than total peptide concentrations in
the Ab samples.
Although the dot-blot analysis is insufficient to estimate the
proportionofparticularoligomericspeciesthatreactwiththeA11or
OC conformation-specific antibodies, the results in Fig. 1G
demonstrate the presence of both A11- and OC-positive oligomers
in Ab samples regardless of the protocol used. Therefore, while
aggregate populations or oligomer sizes determined by DLS and
their effects on membranes and K
+ current may differ in different
preparations, the staining of all these preparations by OC and A11
antibodies implies that they contain oligomeric species with similar
antigenic epitopes, indicating similar peptide conformations and
supramolecularpeptideaggregatestructures.Thisimpliesagainthat
all preparation protocols produce Ab oligomers that affect Kv 1.3
currents and BLM conductivities and is consistent with the
interpretation that peptide aggregates, not residual HFIP, is in
largepartsresponsiblefortheeffectsobservedwithprotocol Isamples.
Overall, our data demonstrate that although the presence of
trace amounts of HFIP in the synthetic Ab samples cannot
account for the effects on K
+ current and membrane conductance,
the synergistic interaction between HFIP and Ab oligomers can
not be excluded. Thus, much higher concentrations of Ab are
required to observe the effects on potassium channels and lipid
bilayers when HFIP-untreated samples are tested. Alternatively,
the properties of the aggregates formed with and without HFIP
might differ. If, in fact, the higher potency of HFIP-prepared
versus NaOH-prepared Ab oligomers that we report is associated
with HFIP effects on the aggregation process, the aggregation
pathway of endogenous Ab in the brain might also be affected by
other fluorinated substances. Indeed, the interactions between Ab
and fluorinated inhalational anesthetics are well documented
[73,74,75,76]. HFIP is structurally related to sevoflurane and is a
sevoflurane metabolite while TFA is an isoflurane metabolite. It is
intriguing to speculate that interactions between fluorinated
anesthetics and/or their metabolites with Ab may affect the
formation of aggregates in the brains of patients undergoing
general anesthesia. Such interactions may underlie a previously
Synthetic Ab Effects on Kv1.3 Channels and BLMs
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[77,78,79,80].
Conclusions
This study demonstrates that small Ab1–42 aggregates affect the
kinetics of voltage-gated Kv 1.3 channels in mammalian cells and
increase membrane conductance. In HFIP-prepared Ab peptide
samples, however, these effects are more potent, possibly due to
differences in the intrinsic properties of the oligomers. Because
both HFIP-dissolved and HFIP-free Ab samples produced
qualitatively similar effects, preparing HFIP-free Ab samples for
testing amyloid effects in biological assays is preferable, as it
eliminates any contribution from the solvent.
Materials and Methods
Preparation of Ab oligomers
Ab1–42 was synthesized as previously described [81]. Lyophi-
lized peptides were resuspended in 50% acetonitrile in water and
re-lyophilized. Several protocols, as described in detail below, were
used to prepare solutions of Ab1–42 oligomers.
HFIP protocol I: Standard Ab oligomer preparation using
HFIP as a solvent [28]. 0.3 mg of Ab1–42 were dissolved and
incubated in 130 mL HFIP for 20 min in 1.5 mL siliconized
Eppendorf tubes, followed by addition of 900 mLD DH 2O and
20 min incubation in the resulting HFIP/water mixture.
Subsequently, the samples were centrifuged at 14,000 g for
15 min. The solvent was evaporated from resulting supernatant
under constant stirring at room temperature in two steps: (1)
exposed to a gentle stream of argon for 10 min; (2) in ambient air
with the Eppendorf tubes closed with perforated caps for 48 hr.
The resulting Ab1–42 concentration was typically 70 mM.
HFIP protocol II: Modified Ab oligomer preparation using
HFIP as a solvent. The protocol described above was modified
in the last evaporation step where Eppendorf tubes were left open
(no caps), allowing more efficient evaporation of the solvent. The
resulting Ab1–42 concentration in these samples was typically
100 mM.
NaOH protocol: Preparation of HFIP-free Ab oligomer
samples using NaOH as a solvent. 0.3 mg Ab1–42 were
dissolved in 30 mL of 100 mM NaOH and incubated for 25 min,
followedbytheadditionof800 mL10 mMsodiumphosphatebuffer
orRingersolutioncontaining10 mMHEPES.TheresultingAb1–42
concentrationwas70 mM.Thesesamplesweresubsequentlykeptin
closed Eppendorf tubes at room temperature. HEPES-buffered
samples were used in the patch-clamp experiments to avoid any
effect of phosphate buffer on recorded currents.
Patch-clamp
The mouse fibroblast cell line L929 that stably expresses mouse
Kv 1.3 potassium channel a subunits was maintained as previously
described [82]. Patch-clamp experiments were performed in
whole-cell mode using an EPC-9 (HEKA Elektronik) amplifier.
Pipettes pulled from borosilicate glass capillaries (Garner Glass)
using a Fleming/Brown micropipette puller (Sutter Instrument
Co.) had resistances of 1.8–2.5 MV when filled with the internal
recording solution that contained 145 mM KF, 10 mM EGTA,
10 mM HEPES, and 2 mM MgCl2 (pH 7.3). The ground
electrode was connected to the bath via an agar bridge. The
external solution contained 2 mM CaCl2, 1 mM MgCl2, 4.5 mM
KCl, 155 mM NaCl, 10 mM D-glucose, and 5 mM HEPES.
Outward K
+ currents were evoked in voltage-clamp mode by
400 ms long depolarizing voltage pulses from 280 mV holding
potential to +40 mV with 10 mV increments and 30 s inter-pulse
intervals to prevent the cumulative inactivation characteristic of
Kv 1.3. The sampling frequency was 10 kHz. The liquid junction
potential was corrected during data acquisition. The cell and
pipette capacitances were compensated during recordings; leak
currents were not subtracted. Data files were recorded using
PULSE/PULSEFIT (HEKA Elektronik) and analyzed using
OriginPro7.5. For the analysis of IK+ activation kinetics, the
currents were normalized to their peak values and the data were
fitted with sigmoidal functions to determine activation time
constants. The inactivation time constants were determined by
fitting the data to single-exponential decay function.
To test the effects of HFIP and TFA, fresh stocks in the External
solution were prepared before each experiment and needed
concentrations were added directly to the gravity-driven perfusion
system. To test the effects of Ab1–42 peptide, the needed amounts
of stock solution were added directly to perfusion system prior to
testing the effects. Although all the effects were not time-
dependent and were observed as soon as the drugs reached the
cells, the cells were exposed to each concentration for 8–
10 minutes for complete solution exchange in the recording
chamber. To ensure that the effects are not due to changes in the
current or cell parameters, the application of the drugs was done
15–20 min after seal formation and only when cell parameters as
well as the current is stabilized so that at least three consequent
control recordings completely overlapped and the cell parameters
are not changed.
Lipid bilayer conductance
Dioleoylphosphatidylcholine (DOPC) and dioleoylphosphatidy-
lethanolamine (DOPE) (Avanti Polar Lipids) were mixed 1:1 to
form BLMs. Electrolyte solutions of various KCl or NaCl
concentrations were buffered with 1 or 10 mM HEPES-Tris at
pH 7.4. BLMs were formed across an aperture (diameter
<150 mm) in a 15 mm thick Teflon (PTFE) septum, punched by
an electric spark and precoated with 2.5% squalane in n-pentane,
by raising the buffer levels underneath two phospholipid
monolayers of the appropriate phospholipid mixtures separated
by the septum [27]. Bilayer formation was monitored by
measuring conductance with silver/silver chloride wires used as
electrodes to apply voltages and record currents. The rear
chamber potential was taken as ground and additions were made
to the front chamber where the solutions were stirred with
magnetic stirrer bars for at least 30 s after each addition. For
measurements of membrane conductance, a voltage ramp
protocol (2150 to +150 mV, at 60 mV/s) was used. All
experiments were performed at room temperature. Voltages were
generated and currents digitized at a resolution of 12 bits with
JCLAMP (SciSoft Co.) driving a National Instruments NI PCI
6024E board. Currents were transduced by an Axopatch 200 A
amplifier (Axon Instruments) connected to the National Instru-
ments board through an NI BNC2090 interface panel.
Dynamic light scattering
DLS experiments were performed using a Malvern Zetanano-
sizer (Malvern, UK) at a scattering angle of 173u in a correlator
time lag window of 0.5 ms–1 s. Distributions of diffusion constants
for Ab1–42 aggregates were obtained through the regularized
inverse Laplace transform (RILT) of experimental correlograms.
Size distributions were then obtained assuming a Stokes-Einstein
relation, D=k BT/(3pgdh), between the diffusion constant D and
the aggregate hydrodynamic diameter, dh.
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19F NMR spectra were recorded at 298 K using a Bruker
DRX400 spectrometer at 376 MHz and a 5 mm QNP
(
1H/
13C/
31P/
19F) NMR probe. XwinNMR (Bruker) was used for
data acquisition and processing. A separate CFCl3 sample was
used as a reference standard for reporting the
19F chemical shifts.
All samples contained 3-(trimethylsilyl)-1-propanesulfonic acid
sodium salt, used to manually shim the spectrometer by
observation of the proton signal. A concentration standard was
generated from HFIP- and TFA-spiked samples without peptide to
quantify concentrations of residual fluorinated substances in
peptide samples.
Dot blot immunochemistry
One mL of each sample was applied to a nitrocellulose
membrane that had been blocked with 10% non-fat milk in
Tris-buffered saline (TBS) containing 0.05% Tween 20 (TBS-T) at
room temperature for 1 h, washed three times for 5 min each with
TBS-T and incubated overnight at 4uC with the conformation-
specific antibodies OC or A11 [7,83] in 5% milk/TBS-T.
Subsequently, the membranes were washed three times for
5 min each with TBS-T, and incubated with horseradish
peroxidase-conjugated anti-rabbit IgG (Promega) diluted
1:10,000 in 5% milk/TBS-T for 1 hour at room temperature.
The blots were washed again three times with TBS-T, one time
with TBS, and then developed with SuperSignal West Femto
Maximum Sensitivity Substrate kit from ThermoScientific (Rock-
ford, IL).
Statistical analysis
The results are presented as mean 6 S.E.M. For electrophys-
iological experiments statistical differences were determined by
two-way Repeated Measures (RM) ANOVA and Student’s t-Test
for two-group comparisons. In order to confirm that each data set
is a normally distributed population of observations, we used the
Shapiro-Wilk normality test for each data set prior to performing
paired t-Test. Analyses were performed using OriginPro version 8
(OriginLab Corporation, Northampton, MA 01060).
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